Molbio Diagnostics Limited
1,259.70
INR
-62.90
(-4.76%)
ISIN
INE869T01028
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Sriram Natarajan
- Full Time Employees
- 2,840
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Plot No. L-46 Verna GO India 403722
- IPO Date
- Aug 17, 2026
- Website
- molbiodiagnostics.com
- Similar Companies
- Business
- Molbio Diagnostics Limited is a biomedical diagnostics company focused on developing and commercializing rapid molecular testing solutions for infectious diseases and other life-science applications. The company delivers a portfolio of products and services designed to enable rapid, accurate, point-of-care and centralized laboratory testing, with an emphasis on simplifying workflows, reducing turnaround times, and enabling scalable deployment across diverse settings. Main products and services: advanced molecular diagnostic assays and kits for pathogen detection; real-time PCR and isothermal amplification platforms; consumables and reagents including primers, probes, and reaction buffers; integrated testing workflows and sample-to-answer solutions; validation, quality control materials, and proficiency testing services; software and data analytics tools for result interpretation, monitoring, and reporting; contract research and development (R&D) services; regulatory and compliance support including validation documentation and regulatory submissions. Latest major company changes: strategic partnerships and collaborations to expand assay menu and validate new targets; recent funding rounds and/or acquisitions to strengthen product pipeline and manufacturing capability; launches of new diagnostic tests and related platforms; organizational reorganizations to streamline operations and scale up production; expansion of geographic footprint through new partnerships, distributors, and regional manufacturing capabilities; updates to branding or corporate structure reflecting growth. Additional context: operates in the in vitro diagnostic (IVD) industry with segments spanning clinical diagnostics, reference laboratories, and point-of-care testing; targets hospitals, clinics, reference labs, and public health organizations; geographic operations extend to multiple regions with manufacturing and distribution networks; founded with headquarters in India; subsidiaries or parent relationships may exist as part of corporate group structures.